Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fifteen brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and fourteen have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $59.53.
Several brokerages have commented on PHVS. Royal Bank Of Canada increased their price target on shares of Pharvaris from $52.00 to $62.00 and gave the company an "outperform" rating in a research note on Wednesday, September 9th. Oppenheimer restated an "outperform" rating on shares of Pharvaris in a research report on Friday, October 23rd. HC Wainwright restated a "buy" rating on shares of Pharvaris in a report on Tuesday, October 6th. Citigroup reaffirmed a "market outperform" rating on shares of Pharvaris in a research report on Wednesday, September 9th. Finally, Rosenblatt Securities set a $60.00 target price on shares of Pharvaris in a research report on Wednesday, September 9th.
View Our Latest Research Report on Pharvaris
Pharvaris Stock Performance
PHVS opened at $32.28 on Wednesday. Pharvaris has a one year low of $23.15 and a one year high of $43.25. The company has a market cap of $2.11 billion, a P/E ratio of -10.35 and a beta of -2.48. The business's 50-day simple moving average is $33.07 and its 200-day simple moving average is $31.36.
Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.04. As a group, analysts predict that Pharvaris will post -2.89 earnings per share for the current fiscal year.
Insider Transactions at Pharvaris
In other Pharvaris news, President Peng Lu sold 100,000 shares of the firm's stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $35.00, for a total transaction of $3,500,000.00. Following the transaction, the president owned 64,953 shares of the company's stock, valued at approximately $2,273,355. This trade represents a 60.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Viviane Monges sold 11,969 shares of Pharvaris stock in a transaction dated Wednesday, September 23rd. The stock was sold at an average price of $33.05, for a total value of $395,575.45. Following the sale, the director owned 5,500 shares in the company, valued at $181,775. This trade represents a 68.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 510,810 shares of company stock valued at $18,563,973 over the last quarter.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in PHVS. Virtu Financial LLC purchased a new stake in Pharvaris in the third quarter valued at approximately $268,000. Jump Financial LLC acquired a new stake in shares of Pharvaris in the third quarter valued at approximately $1,399,000. Nantahala Capital Management LLC acquired a new stake in shares of Pharvaris in the third quarter valued at approximately $4,758,000. Palumbo Wealth Management LLC boosted its holdings in shares of Pharvaris by 40.0% in the third quarter. Palumbo Wealth Management LLC now owns 29,413 shares of the company's stock valued at $933,000 after acquiring an additional 8,409 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Pharvaris during the third quarter worth approximately $114,000.
Pharvaris Company Profile
(
Get Free Report)
Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing oral treatments for hereditary angioedema (HAE) and other conditions involving bradykinin-mediated swelling. The company was founded in 2015 and is based in Leiden, the Netherlands. Its lead candidate, deucrictibant, is an oral small-molecule antagonist of the bradykinin B2 receptor. Pharvaris is studying the candidate in different formulations for both on-demand treatment of HAE attacks and prevention of attacks.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.